FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108052> ?p ?o ?g. }

• W4310108052 endingPage "10602" @default.
• W4310108052 startingPage "10601" @default.
• W4310108052 abstract "Introduction: For most acute myeloid leukemia (AML) patients (pts) an allogeneic stem cell transplantation (HSCT) offers the highest chance of cure. Recently, the European LeukemiaNet (ELN) published updated recommendations on the risk classification in AML pts. In addition to the risk at diagnosis, which is now based on cytogenetics and the mutation status of several genes, a dynamic adjustment according to the measurable residual disease (MRD) status in favorable (fav) and intermediate (int) risk pts at informative time points - such as prior to an allogeneic HSCT - was recommended. A validation of the new ELN2022 risk classification has not been reported. Methods: We retrospectively analyzed 522 AML pts who received an allogeneic HSCT between 2000 and 2021 in first complete remission (CR, 54%), second CR (11%), CR with incomplete count recovery (CRi, 13%), or relapsed/refractory (22%) at our center. Median age at HSCT was 59 (range 16-76) years (y), 53% of pts were younger than 60 y. Conditioning regimens were myeloablative (27%), reduced-intensity (23%) or non-myeloablative (50%). At diagnosis, cytogenetics, and the mutation status of CEBPA, NPM1, and FLT3-ITD were assessed. Using next-generation sequencing we analyzed a panel of 54 recurrently mutated genes in myeloid malignancies (MiSeq platform, Illumina). In pts with material available in remission prior to HSCT, the MRD status based on NPM1mutations, BAALC, MN1, and WT1 expression was evaluated as published previously (Jentzsch 2021). MRD positivity (MRDpos) was defined as positivity of any of the analyzed markers. Median follow up after HSCT was 3.0 y. Results: ELN2022 risk at diagnosis was 22% fav, 26% int, and 52% adverse (adv). Older pts (≥ 60 y at HSCT) had significantly worse ELN2022 genetic risk (P<.001). Comparing the ELN2017 and the new ELN2022, 83% (fav), 70% (int), and 90% (adv) of pts kept their allocation, while 15% and 2% of fav ELN2017 risk pts changed to int and adv ELN2022, 30% of int ELN2017 risk pts changed to adv ELN2022 & 1% and 10% of adv ELN2017 risk pts changed to fav and int ELN2022. Analyzing the c-statistic (area under the curves [AUC]) produced by the ELN2017 and ELN2022 for relapse (AUC2017 = 0.64 vs AUC2022 = 0.64, P=.21) and overall survival (OS) prediction (AUC2017 = 0.60 vsAUC2022 = 0.57, P=.06), the ELN2022 did not perform significantly better. However, the ELN2022 risk at diagnosis impacted cumulative incidence of relapse/progression (CIR, P<.001) and OS (P<.001, Figure 1), which was especially seen in pts < 60 y (CIR P<.001, OFS P<.001), but less so in pts ≥ 60 y at HSCT (CIR P=.002, OS P=.10). At diagnosis, outcomes did not differ significantly with respect to the specific genetic abnormality defining the ELN2022 fav or the ELN2022 int risk. Also a high or low FLT3-ITD allelic ratio (0.5 cut) within the ELN2022 int risk did not result in distinct outcomes (CIR P=.13, OS P=.30). In contrast, within pts harboring adv ELN2022 risk, CIR (P=.05) and OS (P<.001) significantly differed according to the presence of specific genetic abnormalities; i.e. a complex karyotype (at 3 y: CIR 59%, OS 30%), other adverse cytogenetic aberrations (at 3 y: CIR 50%, OS 54%), adverse-risk gene mutation (i.e.ASXL1, RUNX1, or TP53, at 3 y: CIR 47%, OS 58%), or secondary AML-like gene mutations (at 3 y: CIR 30%, OS 73%). When we adjusted fav and int risk pts according to the MRD status at HSCT as proposed by the ELN2022 recommendations, 49% of fav risk pts at diagnosis had persisting MRD and were reclassified as int risk at HSCT while 53% of int risk pts at diagnosis were MRD negative and reclassified as fav risk at HSCT. Outcomes of MRD-adjusted fav risk pts improved (at 3 y: CIR 12%, OS 75%), while that of MRD-adjusted int risk pts (at 3 y: CIR 53%, OS 49%) was similar to that of adv risk pts transplanted in morphologic CR/CRi (at 3 y: CIR 47%, OS 54%). Conclusion: In the context of an allogeneic HSCT, the proposed risk assessments by the ELN2022 significantly impacted outcomes at diagnosis as well as after adjustment according to MRD status prior to HSCT of AML pts. However, it did not perform significantly better than the previous ELN2017 risk stratification. The FLT3-ITD allelic ratio did not significantly impacted outcomes within the ELN2022 int risk, justifying the removal from the risk stratification. Noteworthy, in pts receiving allogeneic HSCT, secondary AML-like gene mutations did not associate with adverse outcomes when no other adverse-risk characteristics were present. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310108052 created "2022-11-30" @default.
• W4310108052 creator A5004233773 @default.
• W4310108052 creator A5021383212 @default.
• W4310108052 creator A5023876572 @default.
• W4310108052 creator A5032516884 @default.
• W4310108052 creator A5039421118 @default.
• W4310108052 creator A5040594919 @default.
• W4310108052 creator A5059485343 @default.
• W4310108052 creator A5065647464 @default.
• W4310108052 creator A5070777861 @default.
• W4310108052 creator A5079124367 @default.
• W4310108052 creator A5079673051 @default.
• W4310108052 creator A5090197729 @default.
• W4310108052 date "2022-11-15" @default.
• W4310108052 modified "2023-10-18" @default.
• W4310108052 title "Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation" @default.
• W4310108052 doi "https://doi.org/10.1182/blood-2022-164842" @default.
• W4310108052 hasPublicationYear "2022" @default.
• W4310108052 type Work @default.
• W4310108052 citedByCount "3" @default.
• W4310108052 countsByYear W43101080522022 @default.
• W4310108052 countsByYear W43101080522023 @default.
• W4310108052 crossrefType "journal-article" @default.
• W4310108052 hasAuthorship W4310108052A5004233773 @default.
• W4310108052 hasAuthorship W4310108052A5021383212 @default.
• W4310108052 hasAuthorship W4310108052A5023876572 @default.
• W4310108052 hasAuthorship W4310108052A5032516884 @default.
• W4310108052 hasAuthorship W4310108052A5039421118 @default.
• W4310108052 hasAuthorship W4310108052A5040594919 @default.
• W4310108052 hasAuthorship W4310108052A5059485343 @default.
• W4310108052 hasAuthorship W4310108052A5065647464 @default.
• W4310108052 hasAuthorship W4310108052A5070777861 @default.
• W4310108052 hasAuthorship W4310108052A5079124367 @default.
• W4310108052 hasAuthorship W4310108052A5079673051 @default.
• W4310108052 hasAuthorship W4310108052A5090197729 @default.
• W4310108052 hasBestOaLocation W43101080521 @default.
• W4310108052 hasConcept C126322002 @default.
• W4310108052 hasConcept C143998085 @default.
• W4310108052 hasConcept C203014093 @default.
• W4310108052 hasConcept C2776863199 @default.
• W4310108052 hasConcept C2777408962 @default.
• W4310108052 hasConcept C2778461978 @default.
• W4310108052 hasConcept C2778729363 @default.
• W4310108052 hasConcept C28328180 @default.
• W4310108052 hasConcept C2911091166 @default.
• W4310108052 hasConcept C54355233 @default.
• W4310108052 hasConcept C71924100 @default.
• W4310108052 hasConcept C86803240 @default.
• W4310108052 hasConceptScore W4310108052C126322002 @default.
• W4310108052 hasConceptScore W4310108052C143998085 @default.
• W4310108052 hasConceptScore W4310108052C203014093 @default.
• W4310108052 hasConceptScore W4310108052C2776863199 @default.
• W4310108052 hasConceptScore W4310108052C2777408962 @default.
• W4310108052 hasConceptScore W4310108052C2778461978 @default.
• W4310108052 hasConceptScore W4310108052C2778729363 @default.
• W4310108052 hasConceptScore W4310108052C28328180 @default.
• W4310108052 hasConceptScore W4310108052C2911091166 @default.
• W4310108052 hasConceptScore W4310108052C54355233 @default.
• W4310108052 hasConceptScore W4310108052C71924100 @default.
• W4310108052 hasConceptScore W4310108052C86803240 @default.
• W4310108052 hasIssue "Supplement 1" @default.
• W4310108052 hasLocation W43101080521 @default.
• W4310108052 hasOpenAccess W4310108052 @default.
• W4310108052 hasPrimaryLocation W43101080521 @default.
• W4310108052 hasRelatedWork W2161603182 @default.
• W4310108052 hasRelatedWork W2345640867 @default.
• W4310108052 hasRelatedWork W2350274480 @default.
• W4310108052 hasRelatedWork W2366793411 @default.
• W4310108052 hasRelatedWork W2367183733 @default.
• W4310108052 hasRelatedWork W2393383561 @default.
• W4310108052 hasRelatedWork W2394313917 @default.
• W4310108052 hasRelatedWork W2936131736 @default.
• W4310108052 hasRelatedWork W2969505416 @default.
• W4310108052 hasRelatedWork W3039046190 @default.
• W4310108052 hasVolume "140" @default.
• W4310108052 isParatext "false" @default.
• W4310108052 isRetracted "false" @default.
• W4310108052 workType "article" @default.